Schwartz, Jill L.

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 1,296

Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.

Delany-Moretlwe, S., Lombard, C., Baron, D., Bekker, L.-G., Nkala, B., Ahmed, K., Sebe, M., Brumskine, W., Nchabeleng, M., Palanee-Philips, T., et al. (2018) · The Lancet Infectious Diseases

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 95

MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel

Cranston, R. D., Lama, J. R., Richardson, B. A., Carballo-Diéguez, A., Kunjara Na Ayudhya, R. P., Liu, K., Patterson, K. B., Leu, C.-S., Galaska, B., Jacobson, C. E., et al. (2017) · Clinical Infectious Diseases

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

Cited by 60